AKT1 and ataxia telangiectasia: AKT phosphorylation was reduced upon treatment with either drug, implicating the EGFR signalling axis in the AKT activation observed in Smarcb1 deficient cells, highlighting the potential use of EGFR inhibitors in the treatment of MRT and AT/RT.